Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Chimerix Inc. (NASDAQ:CMRX) during the second quarter, Holdings Channel reports. The firm bought 81,945 shares of the biopharmaceutical company’s stock, valued at approximately $322,000. Los Angeles Capital Management & Equity Research Inc. owned 0.18% of Chimerix at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Chimerix by 1.0% in the first quarter. Geode Capital Management LLC now owns 286,085 shares of the biopharmaceutical company’s stock valued at $1,461,000 after buying an additional 2,755 shares during the period. Alps Advisors Inc. raised its position in Chimerix by 25.1% in the second quarter. Alps Advisors Inc. now owns 64,919 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 13,023 shares during the period. Royal Bank of Canada raised its position in Chimerix by 9,017.0% in the first quarter. Royal Bank of Canada now owns 24,160 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 23,895 shares during the period. Acadian Asset Management LLC bought a new position in Chimerix during the second quarter valued at about $159,000. Finally, Sabby Management LLC bought a new position in Chimerix during the first quarter valued at about $274,000. Institutional investors own 66.12% of the company’s stock.
Shares of Chimerix Inc. (NASDAQ:CMRX) traded up 1.73% on Wednesday, reaching $5.87. The company’s stock had a trading volume of 359,038 shares. The company’s market capitalization is $271.28 million. The stock has a 50-day moving average price of $4.89 and a 200-day moving average price of $4.77. Chimerix Inc. has a 1-year low of $3.50 and a 1-year high of $43.37.
Chimerix (NASDAQ:CMRX) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.12. Chimerix had a negative return on equity of 34.75% and a negative net margin of 1,356.50%. The business had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.98 million. On average, equities research analysts forecast that Chimerix Inc. will post ($1.78) EPS for the current year.
CMRX has been the topic of a number of research analyst reports. FBR & Co restated a “hold” rating on shares of Chimerix in a research note on Sunday, July 17th. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Wednesday, August 10th. JPMorgan Chase & Co. restated a “hold” rating and set a $7.00 price target on shares of Chimerix in a research note on Tuesday, August 9th. Finally, Piper Jaffray Cos. set a $12.00 price target on Chimerix and gave the stock a “buy” rating in a research note on Thursday, August 18th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $12.28.
In other news, Director John M. Leonard sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $5.03, for a total transaction of $25,150.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider M Michelle Berrey bought 22,417 shares of the business’s stock in a transaction dated Monday, August 29th. The shares were acquired at an average cost of $4.47 per share, for a total transaction of $100,203.99. Following the transaction, the insider now directly owns 281,238 shares in the company, valued at approximately $1,257,133.86. The disclosure for this purchase can be found here. Insiders own 10.50% of the company’s stock.
Chimerix Company Profile
Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix Inc. (NASDAQ:CMRX).
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.